



COVID-19 Research Tools

Defeat the SARS-CoV-2 Variants

InvivoGen



MicroRNA let-7c Regulates Macrophage Polarization

Sami Banerjee, Na Xie, Huachun Cui, Zheng Tan, Shanzhong Yang, Mert Icyuz, Edward Abraham and Gang Liu

This information is current as of August 4, 2022.

J Immunol 2013; 190:6542-6549; Prepublished online 10 May 2013;
doi: 10.4049/jimmunol.1202496
<http://www.jimmunol.org/content/190/12/6542>

Supplementary Material <http://www.jimmunol.org/content/suppl/2013/05/10/jimmunol.1202496.DC1>

References This article **cites 59 articles**, 25 of which you can access for free at:
<http://www.jimmunol.org/content/190/12/6542.full#ref-list-1>

Why *The JI*? Submit online.

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>



MicroRNA let-7c Regulates Macrophage Polarization

Sami Banerjee,^{*1} Na Xie,^{*1} Huachun Cui,^{*} Zheng Tan,^{*} Shanzhong Yang,^{*} Mert Icyuz,^{*} Edward Abraham,[†] and Gang Liu^{*}

Macrophages demonstrate a high level of plasticity, with the ability to undergo dynamic transition between M1 and M2 polarized phenotypes. The role of microRNAs (miRNAs) in regulating macrophage polarization has been largely undefined. In this study, we found that miRNA let-7c is expressed at a higher level in M-BMM (M2 macrophages) than in GM-BMM (M1 macrophages). let-7c levels are also greater in alveolar macrophages from fibrotic lungs as compared with those from normal lungs. let-7c expression was decreased when M-BMM converted to GM-BMM, whereas it increased when GM-BMM converted to M-BMM. LPS stimulation reduced let-7c expression in M-BMM. We found that overexpression of let-7c in GM-BMM diminished M1 phenotype expression while promoting polarization to the M2 phenotype. In contrast, knockdown of let-7c in M-BMM promoted M1 polarization and diminished M2 phenotype expression. We found that let-7c targets C/EBP- δ , a transcriptional factor that plays an important role in inflammatory response. Furthermore, we found that let-7c regulates bactericidal and phagocytic activities of macrophages, two functional phenotypes implicated in macrophage polarization. Our data suggest that the miRNA let-7c plays an important role in regulating macrophage polarization. *The Journal of Immunology*, 2013, 190: 6542–6549.

Macrophages are derived from hematopoietic stem cells through bone marrow myeloid progenitor cells, and show a high degree of plasticity, with the ability to undergo dynamic transition between different functional phenotypes, depending on microenvironmental cues (1–3). Macrophages activated by TLR ligands, such as LPS or IFN- γ , are called M1 macrophages (also referred to as classically activated macrophages) (1–4). In contrast, stimulation of macrophages with Th2 cytokines, such as IL-4 or IL-13, induces the generation of M2-type macrophages (also called alternatively activated macrophages) (1–4). Treatment of bone marrow cells with GM-CSF, termed GM-BMM, and M-CSF, termed M-BMM, lead to the generation of M1 and M2 macrophages, respectively (3, 5–11). M1 macrophages produce high levels of proinflammatory cytokines, including TNF- α , and generate increased amounts of NO through enhanced expression of inducible NO synthase (iNOS), and are critical for eradicating bacterial, viral, and fungal infections (1–4). M2 macrophages are characterized by high expression of markers of alternative activation, such as arginase-1 (Arg1) and Chitinase 3-like 3 (also called YM-1), found in inflammatory

zone 1 (FIZZ1) and participate in the response to parasite infection, tissue remodeling, angiogenesis, and tumor progression (1–3, 12).

The polarization of macrophages has been the focus of numerous recent studies, particularly with regard to transcriptional regulation (1). Transcriptional factors NF- κ B, AP-1, C/EBP- α , PU.1, and IFN regulatory factor 5 participate in TLR-induced M1 activation, whereas STAT6, peroxisome proliferator-activated receptor- γ , IFN regulatory factor 4, C/EBP- β , and Kruppel-like factor 4 are involved in the polarization of macrophages to the M2 phenotype (1, 3). Enzymes involved in epigenetic regulation, such as Jumonji domain containing 3 (JMJD3) and histone deacetylase 3, also play important roles in M2 macrophage polarization (3, 13, 14).

microRNAs (miRNAs) are a class of noncoding small RNAs, 22 nt in length, which bind to the 3' untranslated region (UTR) of target genes, thereby inhibiting their expression through repressing mRNA translation and/or inducing degradation of target gene transcripts (15). miRNAs play essential roles in many cellular and developmental processes, including cell proliferation, apoptosis, and differentiation, as well as organ morphogenesis (15). Aberrant expression of miRNAs is closely associated with progression of pathophysiologic conditions including diabetes, cancer, tissue fibrosis, and cardiovascular disease (16–19).

The role of miRNAs in the regulation of macrophage polarization has been largely undefined (20). In this study, we found that M-BMM demonstrate greater expression of the miRNA let-7c than do GM-BMM. We found that let-7c suppresses polarization of macrophages to the M1 phenotype and enhances M2 polarization. These data suggest that the miRNA let-7c plays a role in regulating macrophage plasticity.

Materials and Methods

Generation of mouse GM-BMM and M-BMM

GM-BMM and M-BMM were derived from bone marrow cells of C57BL/6 or BALB/c mice. In brief, after lysis of RBCs, bone marrow cells were cultured in DMEM media containing 10% FBS and 20 ng/ml GM-CSF (R&D Systems) or 50 ng/ml M-CSF (R&D Systems) for 5 d to establish GM-BMM or M-BMM macrophages. The animal protocol was approved by the University of Alabama at Birmingham Institutional Animal Care and Use Committee.

^{*}Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294; and [†]Wake Forest School of Medicine, Winston-Salem, NC 27157

¹S.B. and N.X. contributed equally to this study.

Received for publication September 5, 2012. Accepted for publication April 8, 2013.

This work was supported by National Institutes of Health Grants HL105473, HL097218, and HL076206 (to G.L.), and American Heart Association Award 10SDG4210009 (to G.L.).

S.B. and G.L. designed the study; S.B., N.X., H.C., Z.T., S.Y., and M.I. performed the experiments; E.A. and G.L. wrote the manuscript.

Address correspondence and reprint requests to Dr. Gang Liu, Department of Medicine, University of Alabama at Birmingham, 901 19th Street South, BMR II 233, Birmingham, AL 35294. E-mail address: gliu@uab.edu

The online version of this article contains supplemental material.

Abbreviations used in this article: Arg1, arginase-1; FIZZ1, found in inflammatory zone-1; FR- β , folate receptor β ; HO-1, heme oxygenase-1; iNOS, inducible NO synthase; JMJD3, Jumonji domain containing 3; MHC-II, MHC class II; miRNA, microRNA; siRNA, small interfering RNA; TAM, tumor-associated macrophage; UTR, untranslated region.

Copyright © 2013 by The American Association of Immunologists, Inc. 0022-1767/13/\$16.00

Quantitative real-time PCR

Probe Master Mix kit (Roche) was used for amplification of *mmu-let-7c* and *sno135*. TaqMan probes for *mmu-let-7c* and *sno135* were purchased from Applied Biosystems. SYBR Green Master Mix kit (Roche) was used for the following genes. Primer sequences were: mouse *GAPDH*: sense, 5'-CGACTTCAACAGCAACTCCACTCTTCC-3'; antisense, 5'-TGGGTGGTCCAGGGTTTCTTACTCCTT-3'; mouse *Arg1*: sense, 5'-TGACTGAAGTAGACAAGCTGGGGAT-3'; antisense, 5'-CGACATCAAAGCTCAGGTGAATCGG; mouse *YM-1*: sense, 5'-ATGAAGCATTGAATGGTCTGAAAG-3'; antisense, 5'-TGAATATCTGACGGTCTGAGGAG-3'; mouse *FIZZ1*: sense, 5'-AGGTCAAGGAAGTCTTGGCCAATCC-3'; antisense, 5'-AAGCACACCCAGTAGCAGTCATCCC-3'; mouse *iNOS*: sense, 5'-ATCTTTGCCACCAAGATGGCCTGG-3'; antisense, 5'-TTCTGTGCTGTGCTACAGTTCGG-3'; mouse *C/EBP-δ*: sense 5'-AACTTGATTCTCTGCTTGCCTCTACTTTC-3'; antisense, 5'-CCGCAAACATTACAATTACTGGCTTTT-3'; mouse *JMJD3*: sense, 5'-TACCCCGAGCATCTATTTGGAGAGC-3'; antisense, 5'-TAAGTTGAGCCGAACTGAACCCAGCC-3'; mouse *IL-12 p40*: sense, 5'-CCAAATTACTCCGGACGGTTCAC-3'; antisense, 5'-CAGACAGAGACGCCATCCACAT-3'; mouse folate receptor β (*FR-β*): sense, 5'-CTTCAACTGGGATCACTGTGGCA-3'; antisense, 5'-CATCCAGGAAACGCTCTTTACGC-3'; mouse *CCR7*: sense, 5'-AAACGTGTGGTGGTGGCTCTC-3'; antisense, 5'-ACCGTGGTATTCTCGCCGATG-3'; mouse *CD36*: sense, 5'-TTTCAA-TGGAAAGGATAACATAAGCAAAGT-3'; antisense, 5'-TCAACAAAAGG-TGGAAAGGAGGCT-3'.

Western blotting

Western blotting was performed as previously described (21). Mouse anti-actin Ab, anti-GAPDH, and rabbit anti-C/EBP-δ Abs were from Santa Cruz. Rabbit anti-IκB-α, rabbit anti-pp-38, rabbit anti-p-Erk, and rabbit anti-p-STAT6 Abs were from Cell Signaling.

Luciferase assay

cDNA containing the full-length C/EBP-δ 3' UTR sequence was obtained by PCR amplification using a human C/EBP-δ EST (Open Biosystems) as a template and cloned into SpeI and HindIII sites of pMir-Report Luciferase vector (Applied Biosystems). The sequences of the primers used for the PCR amplification were: sense: 5'-GGACTAGTCAGTTCTTCAAGCAGCTGCC-3'; and antisense: 5'-CCAAGCTGTGAGCATGCTCAGTCTTTTCC-3'. The resulting construct was designated as pMir-Report-C/EBP-δ. HEK-293T cells were transfected with 5 ng pMir-Report-C/EBP-δ and 20 nM control mimics or 20 nM mimics for *let-7c* using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. After 72 h of transfection, luciferase activity in the cells was determined using a Luciferase Assay System (Promega).

Bacteria killing assay

Bacteria killing capability of BMM was performed as described previously (22). A total of 0.1×10^9 CFU/ml *Escherichia coli* (BL21DE3pLysS) was added to GM-BMM or M-BMM in 96-well plates. Plates were centrifuged for 5 min at $400 \times g$ and incubated for 1 h at 37°C. Supernatants from each well were subject to 100-fold dilutions, and 100 μl of the diluted supernatants was plated on Luria broth agar plates. The plates were incubated at 37°C overnight and bacterial colonies enumerated. Data were presented as CFU/ml; CFU/ml = number of bacterial colonies \times dilution factor/volume of the diluted supernatants plated.

Phagocytosis assay

Phagocytosis assay was performed as previously described by our group (23). In brief, phagocytosis of PKH26-labeled apoptotic thymocytes by GM-BMM or M-BMM (efferocytosis) was evaluated by addition of 0.5×10^6 apoptotic thymocytes suspended in 500 μl RPMI 1640 media containing 10% FBS to the cells, followed by incubation at 37°C for 30 min. Macrophages were then washed five times with cold PBS, resuspended in PBS containing 1% albumin, FITC-conjugated anti-CD11b (macrophage marker) Ab, and allophycocyanin-conjugated anti-CD90.2 Ab (thymocyte marker), and analyzed by flow cytometry. The phagocytic index was calculated as the ratio of FITC⁺PKH26⁺allophycocyanin⁻ cells to all cells gated. Engulfed thymocytes are not accessible to the allophycocyanin-conjugated anti-CD90.2 Ab. Therefore, FITC⁺PKH26⁺allophycocyanin⁻ cells are macrophages that have engulfed PKH-labeled thymocytes. For FcR-mediated phagocytosis, red fluorescent-labeled carboxylate-modified beads (Invitrogen) were preincubated with mouse IgG (5 mg/ml) for 1 h. The beads were then incubated with macrophages for 15 min. The cells were washed three times and cell suspension prepared. Flow cytometry assays were performed.

Flow cytometry assay

GM-BMM cells were trypsinized and suspended in PBS containing 1% BSA and 1 μg/ml Fcγ blocker (rat anti-mouse CD16/CD32; BD Pharmingen) for 30 min. The cells were then incubated with 1 μg/ml FITC-conjugated mouse anti-MHC class II (anti-MHC-II) mAb for 30 min. Cells were washed once and flow cytometry was performed.

Transfection of miRNAs and small interfering RNAs

GM-BMM and M-BMM were transfected with 20 nM miRNA mimics, 20 nM miRNA inhibitors, or 20 nM small interfering RNAs (siRNAs) using HiperFect transfection reagent (Qiagen) according to the manufacturer's instructions. Control and *let-7c* mimics were from Life Technologies. Control inhibitors and inhibitors against *let-7c* were from Exiqon. Control siRNA and C/EBP-δ siRNA were from Dharmacon.

Experimental pulmonary fibrosis model

Bleomycin-induced mouse pulmonary fibrosis model was established as previously described by our group (24). Eight-week-old male C57BL/6 mice were used in this study. Alveolar macrophages were obtained through bronchoalveolar lavage. In brief, cells from the bronchoalveolar lavage were plated in 24-well plates for 30 min. The plates were then washed extensively to remove unattached cells. Attached macrophages were lysed and RNA isolated.

Statistical analysis

One-way ANOVA followed by the Bonferroni test was performed for multiple-group comparisons. The Student *t* test was used for comparison between two groups. A *p* value <0.05 was considered statistically significant.

Results

M-BMM demonstrate greater expression of *let-7c* than do GM-BMM

To study macrophage polarization and plasticity, we chose GM-BMM and M-BMM as macrophages representative of the two opposite polarized states (M1 versus M2) as their phenotypes have been well defined in numerous studies (5–11). We found that M-BMM exhibit a considerably higher level of *let-7c* than do GM-BMM (Fig. 1A). Genetic background of mice had no effect on this phenomenon because *let-7c* also demonstrated significantly greater levels in M-BMM than in GM-BMM that were derived from BALB/c mice (Supplemental Fig. 1). Our initial findings suggest that *let-7c* participates in macrophage polarization.

As TLR4 stimulation promotes and induces M1 polarization (4), we next asked whether TLR4 stimulation affects *let-7* levels in M-BMM. We found that *let-7c* levels are significantly reduced in LPS-treated M-BMM (Fig. 1B). These data indicate that a decrease in *let-7c* may be involved in the promotion of M1 phenotype expression.

To examine whether *let-7c* contributes to the plasticity of macrophage polarization, we attempted to convert one population into another by culturing GM-BMM macrophages with M-CSF and M-BMM macrophages with GM-CSF. As shown in Fig. 1C, GM-BMM-to-M-BMM conversion resulted in increased *let-7c*, whereas M-BMM-to-GM-BMM conversion led to decreased *let-7c* expression. Of note, the alteration in *let-7c* levels in the converted GM-BMM or M-BMM was less than that between GM-BMM and M-BMM. These data suggest that the conversion by culture of GM-BMM or M-BMM with M-CSF or GM-CSF is incomplete.

To determine whether the increase in *let-7c* during GM-BMM-to-M-BMM conversion occurs in pathologic conditions where M2 macrophages play important roles (25–28), we examined *let-7c* levels in alveolar macrophages isolated from fibrotic mouse lungs. These macrophages are known to express M2 phenotypes (25–28). We found that *let-7c* is upregulated in alveolar macrophages isolated from fibrotic mouse lungs, compared with macrophages from




FIGURE 1. M-BMM demonstrate greater expression of let-7c than do GM-BMM. **(A)** Mouse bone marrow cells were cultured in 50 $\mu\text{g}/\text{ml}$ M-CSF or 20 $\mu\text{g}/\text{ml}$ GM-CSF for 7 d to establish M-BMM and GM-BMM. RNA was isolated and levels of let-7c determined by real-time PCR. Small nucleolar RNA, sno135, was used as an internal control. $n = 3$; mean \pm SD. $*p < 0.05$ compared with GM-BMM. **(B)** M-BMM were treated without or with 100 ng/ml LPS for 24 h. RNA was isolated and levels of let-7c determined. $n = 3$; mean \pm SD. $*p < 0.05$ compared with untreated GM-BMM. **(C)** M-BMM and GM-BMM were established as in (A). The cells were then cultured in fresh media containing GM-CSF or M-CSF for 5 more days to induce the transition from M-BMM to GM-BMM or vice versa. RNA was isolated and levels of let-7c determined. $n = 3$; mean \pm SD. $*p < 0.05$, $**p < 0.01$ compared with the control groups. **(D)** Alveolar macrophages were isolated from lungs of normal or bleomycin-treated mice, as described in *Materials and Methods*. RNA was isolated and levels of let-7c, Arg1, and JMJD3 were determined. $n = 5$ for each group; mean \pm SD. $**p < 0.01$, $***p < 0.001$ compared with the control group. The experiments were performed two to three times with similar results.

normal mouse lungs (Fig. 1D). As expected, the M2 macrophage marker, Arg1, and JMJD3, a histone demethylase that was previously shown to have higher levels in M2 macrophages (6), were increased in alveolar macrophages isolated from fibrotic mouse lungs (Fig. 1D). Given the established role of M2 macrophages in lung remodeling and fibrosis (25–28), these data suggest that let-7c may participate in pulmonary fibrosis through modulating alveolar macrophage polarization. Further studies on the effect of let-7c-regulated alveolar macrophages on pulmonary fibrosis will likely provide insight into this hypothesis. Homogenous staining of CD11c, a specific surface marker of alveolar macrophages (29), indicates the purity of these cells (Supplemental Fig. 2).

Overexpression of let-7c diminishes the expression of M1 phenotypes in GM-BMM

To determine whether let-7c participates in macrophage polarization, we transfected GM-BMM, which have lower levels of let-7c than do M-BMM, with mimics for let-7c. We found that overexpression of let-7c in GM-BMM diminishes the basal levels of CCR7 (Fig. 2A), a typical marker of GM-BMM (30). These data suggest that let-7c is a negative regulator of M1 macrophage phenotypes.

TLR4 stimulation promotes M1 macrophage polarization, as characterized by enhanced expression of proinflammatory cyto-




FIGURE 2. Overexpression of let-7c diminishes the expression of M1 phenotypes in GM-BMM. **(A)** GM-BMM were transfected with 20 nM control mimics or mimics for let-7c. Three days after transfection, cells were harvested and RNA isolated. Levels of CCR7 were determined. $n = 3$; mean \pm SD. $*p < 0.05$ compared with the control group. **(B)** GM-BMM were transfected with 20 nM control mimics or mimics for let-7c. Three days after transfection, the cells were treated with 100 ng/ml LPS for 6 h. Levels of IL-12 and iNOS were determined. $n = 3$; mean \pm SD. $*p < 0.05$ compared with the control group. **(C)** GM-BMM were transfected with 20 nM control mimics or mimics for let-7c. Three days after transfection, the cells were treated without or with 100 ng/ml LPS for 6 h. The surface levels of MHC-II were determined by flow cytometry analysis. **(D)** Statistical analysis of MHC-II⁺ cells in each experimental condition in (C). $n = 3$; mean \pm SD. A second experiment provided similar results. $*p < 0.05$ compared with the control group without LPS treatment, $\#p < 0.05$ compared with the control group without LPS treatment, $***p < 0.001$ compared with the control group with LPS treatment.

kines, such as IL-12, and iNOS (4, 7, 31). To investigate the effect of let-7c on the proinflammatory response of macrophages, we treated GM-BMM transfected with control mimics or mimics for let-7c with LPS. As shown in Fig. 2B, the increases in IL-12 and iNOS expression normally found after LPS treatment were diminished in let-7c transfected GM-BMM. In addition, we examined MHC-II expression, one of the surface markers of M1 macrophages (32, 33), in GM-BMM transfected with control mimics or mimics for let-7c. As shown in Fig. 2C and 2D, transfection with let-7c diminished levels of MHC-II in GM-BMM. Furthermore, let-7c attenuated LPS-enhanced MHC-II levels on the surface of GM-BMM. These data suggest that let-7c is a negative regulator of proinflammatory responses induced by TLR4 stimulation in GM-BMM. Of note, the moderate effect of let-7c on the suppression of the M1 phenotypes suggests that it may be just one of the miRNAs that are involved in this process.

Overexpression of let-7c promotes GM-BMM transition to the M2 phenotype

Because our experiments found that overexpression of let-7c in GM-BMM diminishes their expression of M1 phenotypes after LPS exposure, we next asked whether let-7c also participates in macrophage plasticity by promoting the transition of GM-BMM to the M-BMM or M2 phenotype. To address this question, we transfected GM-BMM with control mimics or mimics for let-7c and then first examined the expression of a typical M-BMM marker, FR- β (34). As shown in Fig. 3A, GM-BMM transfected with let-7c demonstrated increased levels of FR- β , compared with GM-BMM transfected with control mimics. These data suggest that let-7c can drive the transition of GM-BMM toward the M-BMM phenotype.

Because IL-4 is a classical Th2 cytokine that induces M2 macrophage polarization (4), we evaluated the effect of let-7c on IL-4-induced M2 polarization. In these experiments, we treated GM-BMM that were transfected with control mimics or mimics for let-7c with IL-4. We found that IL-4 induced expression of Arg1, FIZZ1, and YM-1 in GM-BMM transfected with let-7c is significantly greater than that in GM-BMM cells transfected with control mimics (Fig. 3B). Taken together, these data suggest that let-7c promotes the transition of GM-BMM to the M2 phenotype.

A previous report showed that let-7c enhances heme oxygenase-1 (HO-1) expression (35). Because HO-1 has been shown to be involved in macrophage polarization (36), we determined whether HO-1 affects let-7c-regulated M2 polarization. We treated let-7c mimics transfected GM-BMM with specific HO-1 inhibitors, zinc protoporphyrin, before IL-4 exposure. As shown in Supplemental Fig. 3, let-7c enhanced IL-4-induced expression of M2 marker Fizz1. The enhanced expression of IL-4-induced Fizz1 was diminished when HO-1 was inhibited.

Knockdown of let-7c promotes transition of M-BMM to the M1 phenotype and diminishes the expression of M2 phenotypes in M-BMM

We have shown that let-7c suppresses expression of the M1 phenotype and promotes transition to the M2 phenotype in GM-BMM. We next asked whether knocking down let-7c in M-BMM, which have higher levels of let-7c than do GM-BMM, demonstrates an effect opposite to that observed in GM-BMM that are transfected with let-7c. To answer this question, we transfected M-BMM with control inhibitors or inhibitors against let-7c. As shown in Fig. 4A, let-7c knockdown enhanced LPS-induced expression of IL-12 and iNOS. Given our findings that GM-BMM with overexpression of let-7c have diminished proinflammatory response to LPS, these data establish that let-7c has a suppressive role in M1 macrophage polarization.




FIGURE 3. Overexpression of let-7c promotes GM-BMM transition to the M2 phenotype. (A and B) GM-BMM were transfected with 20 nM control mimics or mimics for let-7c. Three days after transfection, the cells were treated without or with 2 ng/ml IL-4 for 24 h. Levels of FR- β (A) and Arg1, FIZZ1, and YM-1 (B) were determined. $n = 3$; mean \pm SD. A second experiment provided similar results. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ compared with the control groups.




FIGURE 4. Knockdown of let-7c promotes transition of M-BMM to the M1 phenotype and diminishes the expression of M2 phenotypes in M-BMM. (A) M-BMM were transfected with 20 nM control inhibitors or inhibitors against let-7c. Three days after transfection, the cells were treated without or with 100 ng/ml LPS for 6 h. Levels of IL-12 and iNOS were determined. $n = 3$; mean \pm SD. * $p < 0.05$ compared with the control groups. (B and C) M-BMM were transfected with 20 nM control inhibitors or inhibitors against let-7c. Three days after transfection, the cells were treated without or with 2 ng/ml IL-4 for 24 h. Levels of FR- β (B) and Arg1, FIZZ1, and YM-1 (C) were determined. $n = 3$; mean \pm SD. A second experiment provided similar results. * $p < 0.05$, ** $p < 0.01$ compared with the control groups.

Because our experiments demonstrated that knockdown of let-7c promotes M-BMM transition to M1 phenotype, we next asked whether knockdown of let-7c has any effect on expression of the M2 phenotype. As shown in Fig. 4B, knockdown of let-7c diminished the levels of FR- β . Furthermore, knockdown of let-7c diminished IL-4-induced progression of M-BMM to the M2 phenotype, as shown by a decrease in IL-4-induced Arg1, FIZZ1, and YM-1 in these cells (Fig. 4C). These data suggest that let-7c participates in sustaining the M2 macrophage phenotype.

let-7c does not affect signaling events that are immediately downstream of the engagement of LPS or IL-4 with their receptors

LPS binding to TLR4 induces I κ B- α degradation, which leads to NF- κ B activation (37). In addition, LPS stimulation activates MAPKs, such as Erk and p38 (37). Activation of NF- κ B and MAPKs is required for the proinflammatory responses that occur in macrophages after LPS stimulation (37). To determine whether let-7c inhibits signaling events that are immediately downstream of engagement of TLR4 by LPS, we examined I κ B- α degradation as well as phosphorylation of Erk and p38 in LPS-treated GM-BMM that were transfected with control mimics or mimics for let-7c. As shown in Supplemental Fig. 4A, overexpression of let-7c had no effect on LPS-induced I κ B- α degradation or phosphorylation of Erk and p38 in GM-BMM. Knockdown of let-7c in M-BMM also did not affect LPS-induced I κ B- α degradation or phosphorylation of Erk or p38 (Supplemental Fig. 4C). These data suggest that inhibition of macrophage transition to the M1 phenotype by let-7c is not caused by alterations in cytoplasmic transduction of TLR4 signaling.

IL-4 stimulation induces STAT6 phosphorylation and translocation to the nucleus (6, 38). Activation of STAT6 is required for IL-4-induced polarization of macrophages to the M2 phenotype (6, 38). To determine whether let-7c enhances STAT6 activation by IL-4, thereby augmenting IL-4-induced M2 macrophage polarization, we examined STAT6 phosphorylation in IL-4-treated GM-BMM that were transfected with control mimics or mimics for let-7c. As shown in Supplemental Fig. 4B, overexpression of let-7c had no effect on IL-4-induced STAT6 phosphorylation in GM-BMM. Knockdown of let-7c in M-BMM also did not affect IL-4-induced STAT6 phosphorylation (Supplemental Fig. 4D). These data suggest that the promotion of development of the M2 phenotype by let-7c is not caused by alterations in IL-4-induced STAT6 activation.

let-7c targets C/EBP- δ


To delineate the mechanism by which let-7c regulates macrophage polarization, we searched predicted targets of let-7c that could participate in this process and found that the transcriptional factor C/EBP- δ is among let-7c targets. C/EBP- δ has been shown to regulate proinflammatory response to LPS (39–41). To determine whether let-7c targets C/EBP- δ in macrophages, we transfected GM-BMM with control mimics or mimics for let-7c. As shown in Fig. 5A and 5B, overexpression of let-7c diminished both mRNA and protein expression of C/EBP- δ . Next, we cloned the 3' UTR of C/EBP- δ into a luciferase reporter and cotransfected it with control or let-7c mimics. As shown in Fig. 5C, let-7c downregulated luciferase activity of the reporter that contained the 3' UTR of C/EBP- δ , suggesting that let-7c directly targets C/EBP- δ . To determine whether knockdown of C/EBP- δ recapitulates the suppressive effect of let-7c on the development of the

M1 phenotype, we transfected GM-BMM with control siRNA or C/EBP- δ siRNA and found that C/EBP- δ knockdown attenuates LPS-induced expression of IL-12 and iNOS (Fig. 5D). In addition, C/EBP- δ knockdown diminished the levels of MHC-II in untreated GM-BMM (Fig. 5E). C/EBP- δ knockdown also attenuated LPS-enhanced MHC-II levels on the macrophage surface (Fig. 5E). In addition, C/EBP- δ knockdown diminished the levels of CCR7 in GM-BMM (Fig. 5F). In contrast, knockdown of C/EBP- δ enhanced the expression of M2 phenotype, as indicated by increased levels of FR- β (Fig. 5F). As expected, C/EBP- δ siRNA reduced the expression of C/EBP- δ in GM-BMM (Fig. 5G). These data confirmed previous findings that C/EBP- δ is a negative regulator of the proinflammatory response to TLR4 stimulation (39–41). These data also suggest that C/EBP- δ contributes, at least in part, to the effect of let-7c on macrophage polarization.

let-7c regulates cellular functions associated with M1 and M2 phenotypes

We have shown that let-7c suppresses M1 macrophage polarization and promotes M2 macrophage activation. We next asked whether let-7c regulates cellular functions associated with the M1 and M2 phenotypes. It was previously shown that M2 macrophages possess greater activity to engulf apoptotic cells than do M1 macrophages (42–45), which we confirmed in Fig. 6A. Next, we evaluated the effect of let-7c on the engulfment of apoptotic thymocytes by GM-BMM and M-BMM. As shown in Fig. 6B, overexpression of let-7c in GM-BMM significantly enhanced their ability to uptake apoptotic cells. In contrast, knockdown of let-7c diminished the ability of M-BMM cells to engulf apoptotic thymocytes (Fig. 6C). The effect of let-7c on the activity of macrophages to engulf ap-

FIGURE 5. let-7c targets C/EBP- δ . **(A)** GM-BMM were transfected with 20 nM control mimics or mimics for let-7c. Three days after transfection, levels of C/EBP- δ were determined by real-time PCR. $n = 3$; mean \pm SD. * $p < 0.05$ compared with the control group. **(B)** GM-BMM were transfected with 20 nM control mimics or mimics for let-7c. Three days after transfection, levels of C/EBP- δ and actin were determined by Western blotting. **(C)** Five nanograms pMIR-Reporter-C/EBP- δ 3'UTR was cotransfected with 20 nM control mimics or mimics for let-7c into HEK-293T cells. Twenty-four hours after transfection, luciferase activity in the cells was determined. $n = 3$; mean \pm SD. *** $p < 0.001$ compared with the control group. **(D)** GM-BMM were transfected with 20 nM control siRNAs or siRNAs targeting C/EBP- δ . Three days after transfection, the cells were treated without or with 100 ng/ml LPS for 6 h. Levels of IL-12 and iNOS were determined by real-time PCR. $n = 3$; mean \pm SD. ** $p < 0.01$ compared with the control group treated with LPS. **(E)** GM-BMM were transfected with 20 nM control siRNAs or siRNAs targeting C/EBP- δ . Three days after transfection, the cells were treated without or with 100 ng/ml LPS for 6 h. The surface levels of MHC-II were determined by flow cytometry analysis. **(F)** GM-BMM were transfected with 20 nM control siRNAs or siRNAs targeting C/EBP- δ . Three days after transfection, levels of CCR7 and FR- β were determined by real-time PCR. $n = 3$; mean \pm SD. ** $p < 0.01$, *** $p < 0.001$ compared with the control group. **(G)** GM-BMM were transfected with 20 nM control siRNAs or siRNAs targeting C/EBP- δ . Three days after transfection, levels of C/EBP- δ and actin were determined by Western blotting.






FIGURE 6. *let-7c* regulates cellular functions associated with M1 and M2 phenotypes. **(A)** A total of 0.5×10^6 apoptotic thymocytes was added to GM-BMM and M-BMM macrophages, and phagocytosis assays were performed. Phagocytic index was calculated as described in *Materials and Methods*. $n = 3$; mean \pm SD. *** $p < 0.001$ compared with the control group. **(B)** GM-BMM were transfected with 20 nM control mimics or mimics for *let-7c*. Phagocytosis assays were performed as in **(A)**. $n = 3$; mean \pm SD. ** $p < 0.01$ compared with the control group. **(C)** M-BMM were transfected with 20 nM control inhibitors or inhibitors against *let-7c*. Phagocytosis assays were performed as in **(A)**. $n = 3$; mean \pm SD. * $p < 0.05$ compared with the control group. **(D and E)** GM-BMM or M-BMM were transfected with 20 nM control mimics, mimics for *let-7c*, control inhibitors, or inhibitors against *let-7c*. Levels of CD36 were determined. ** $p < 0.01$, *** $p < 0.001$ compared with the control group. **(F)** GM-BMM were transfected with 20 nM control mimics or mimics for *let-7c*. Three days after transfection, live *E. coli* was added into the media. One hour after incubation, the supernatants were removed and cultured on Luria broth agar plates at 37°C for 24 h. The bacteria colonies were enumerated and the CFU of *E. coli* in the supernatants were determined. $n = 3$; mean \pm SD. *** $p < 0.001$ compared with the control group. A second experiment provided similar results. **(G and H)** GM-BMM or M-BMM were transfected with 20 nM control mimics, mimics for *let-7c*, control inhibitors, or inhibitors against *let-7c*. Red fluorescent-labeled carboxylate-modified beads opsonized with mouse IgG (5 mg/ml) were then incubated with macrophages for 15 min. The cells were washed three times and cell suspension prepared. Flow cytometry assays were performed. * $p < 0.05$, ** $p < 0.01$ compared with the control group.

optotic thymocytes may be caused by alterations of the levels of CD36, a receptor that mediates clearance of apoptotic cells (46), on the surface of *let-7c*-modulated macrophages (Fig. 6D, 6E). These data are consistent with our findings that overexpression of *let-7c* in GM-BMM promotes their transition to the M2 phenotype and knockdown of *let-7c* in M-BMM promotes their transition to the M1 phenotype.

M1 macrophages are known to have high bactericidal activity (1, 2, 4). To determine whether *let-7c* regulates bactericidal activity, we transfected GM-BMM with control or *let-7c* mimics. We found that overexpression of *let-7c* significantly diminished the bactericidal activity of GM-BMM (Fig. 6F). These data suggest that *let-7c* suppresses macrophage functions associated with the M1 phenotype.

Fig. 6G and 6H showed that overexpression of *let-7c* decreased, whereas knockdown of *let-7c* enhanced FcR-mediated phagocytosis. Given that enhanced FcR-mediated phagocytosis is a phenotype of inflammatorily activated macrophages, these data are consistent with the findings that *let-7c* attenuated M1 activation of macrophages.

Discussion

In these experiments, we found that *let-7c* promotes M2 macrophage polarization and suppresses M1 polarization. However, *let-7c* appeared to have no effect on the cytoplasmic signaling events that are downstream of the engagement of LPS or IL-4 with their receptors, including $\text{I}\kappa\text{B-}\alpha$ degradation, MAPK activation, or STAT6 phosphorylation (38, 47). These findings indicate that *let-7c* may regulate TLR4 and IL-4 signaling through interaction with nuclear targets. Consistent with this role for *let-7c*, we found that *let-7c* regulates C/EBP- δ , an important transcriptional factor that has been shown to be required for a sustained TLR4-induced inflammatory response (40). Multiple lines of evidence in our study support a direct regulation of C/EBP- δ by *let-7c*: first, overexpression of *let-7c* downregulates C/EBP- δ in GM-BMM at both mRNA and protein levels; second, the 3' UTR in C/EBP- δ transcripts contains a *let-7c* binding site; and third, the C/EBP- δ 3' UTR is responsive to *let-7c* regulation.

Our data suggest that C/EBP- δ may be involved in mediating the effects of *let-7c* on macrophage polarization. This supposition is based on our findings that knocking down C/EBP- δ diminishes M1 macrophage activation whereas enhancing M2 polarization.

Although the role of C/EBP- δ in M1 activation has been studied (39–41), it is unknown how C/EBP- δ regulates M2 macrophage polarization. It is possible that C/EBP- δ may modulate STAT6 binding to the promoters of the M2 macrophage marker genes, an action similar to its regulation of NF- κ B in cellular responses that promote M1 activation (40). It is also likely that C/EBP- δ may interfere with C/EBP- β in inducing the M2 marker genes. C/EBP- β has been shown to be required for the expression of M2 macrophage phenotype (48). However, C/EBP- δ may not be the sole mediator of let-7c in regulating macrophage polarization because knockdown of C/EBP- δ does not duplicate all of the effects of let-7c in macrophages. Indeed, recent studies found that let-7 family members repress the expression of TLR4 and cytokine-inducible Src homology 2-containing protein in cholangiocytes and contributes to epithelial immune responses against *Cryptosporidium parvum* infection (49, 50).

We found that let-7c is expressed at higher levels in alveolar macrophages from fibrotic mouse lungs than in alveolar macrophages from normal mouse lungs. These data are concordant with previous findings that alveolar macrophages in fibrotic lungs possess the M2 macrophage phenotype (25–28). One of the main functions of M2 macrophages is to promote wound repair. M2 macrophages are also implicated in fibrotic diseases that feature uncontrolled, excessive collagen deposition and production of extracellular matrix proteins. Therefore, targeting let-7c in alveolar macrophages may have potential utility in the treatment of pulmonary fibrosis.

Our experiments demonstrated that let-7c not only regulates the expression of M1 and M2 macrophage markers, but also controls macrophage functions associated with the M1 and M2 states. We found that overexpression of let-7c in GM-BMM diminished their activity to kill bacteria, a typical function of M1 macrophages (1, 2, 4). We also found that overexpression of let-7c in GM-BMM enhanced their ability to engulf apoptotic cells, an event that has been implicated in M2 macrophage polarization (42–45). Concordantly, knockdown of let-7c in M-BMM diminished their capability to engulf apoptotic cells. All of these data suggest that let-7c has a role in controlling the plasticity of macrophage differentiation. Therefore, any dysregulation of let-7c could impair the ability of macrophages to rapidly switch differentiation state, which is required for macrophages to mount an appropriate response to environmental cues. Conceivably, a failure of appropriate macrophage polarization will lead to pathologic conditions.

Let-7 is one of the first miRNAs identified and initially was found to control developmental timing in *Caenorhabditis elegans* (51, 52). Members of let-7 family have been shown to either promote or inhibit inflammatory response to various stimuli (50, 53–58). The differential regulation might be because of different cell populations and stimuli examined. A number of studies also found that let-7 is frequently downregulated in cancers, and that the loss of the tumor-suppressor activity of let-7 is associated with worse outcomes in cancer patients (59). Recently, tumor-associated macrophages (TAMs) have been shown to have a major role in the regulation of tumor progression by controlling angiogenesis and immune suppression (12). TAMs have been shown to share some of the characteristics of the M2 macrophage phenotype (12). Levels of let-7 family members in TAMs are currently unknown. Although our experiments showed that let-7c promotes M2 polarization and suppressed M1 activation, it is presently not possible to infer that reduced expression of let-7c in TAMs, as is true in various cancer cells (59), may diminish their degree of M2 polarization.

In these studies, we found that M-BMM demonstrate greater expression of let-7c than do GM-BMM. Furthermore, we dem-

onstrated that when M-BMM were converted to GM-BMM by being cultured in GM-CSF or vice versa, the levels of let-7c also reversed. Although the mechanisms by which let-7c levels are regulated during the transition between the M1 and M2 polarization remains to be determined, our data suggest that dynamic changes in the expression of let-7c, and likely other miRNAs (20, 33, 60), may contribute to an innate mechanism that may be used by macrophages to respond effectively to environmental cues.

Disclosures

The authors have no financial conflicts of interest.

References

- Lawrence, T., and G. Natoli. 2011. Transcriptional regulation of macrophage polarization: enabling diversity with identity. *Nat. Rev. Immunol.* 11: 750–761.
- Murray, P. J., and T. A. Wynn. 2011. Obstacles and opportunities for understanding macrophage polarization. *J. Leukoc. Biol.* 89: 557–563.
- Liu, G., and E. Abraham. 2013. MicroRNAs in immune response and macrophage polarization. *Arterioscler. Thromb. Vasc. Biol.* 33: 170–177.
- Mosser, D. M., and J. P. Edwards. 2008. Exploring the full spectrum of macrophage activation. *Nat. Rev. Immunol.* 8: 958–969.
- Martinez, F. O., S. Gordon, M. Locati, and A. Mantovani. 2006. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. *J. Immunol.* 177: 7303–7311.
- Satoh, T., O. Takeuchi, A. Vandebon, K. Yasuda, Y. Tanaka, Y. Kumagai, T. Miyake, K. Matsushita, T. Okazaki, T. Saitoh, et al. 2010. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. *Nat. Immunol.* 11: 936–944.
- Krausgruber, T., K. Blazek, T. Smallie, S. Alzabin, H. Lockstone, N. Sahgal, T. Hussell, M. Feldmann, and I. A. Udalova. 2011. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. *Nat. Immunol.* 12: 231–238.
- Fleetwood, A. J., T. Lawrence, J. A. Hamilton, and A. D. Cook. 2007. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. *J. Immunol.* 178: 5245–5252.
- Verreck, F. A., T. de Boer, D. M. Langenberg, M. A. Hoeve, M. Kramer, E. Vaisberg, R. Kastelein, A. Kolk, R. de Waal-Malefyt, and T. H. Ottenhoff. 2004. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. *Proc. Natl. Acad. Sci. USA* 101: 4560–4565.
- Fleetwood, A. J., H. Dinh, A. D. Cook, P. J. Hertzog, and J. A. Hamilton. 2009. GM-CSF- and M-CSF-dependent macrophage phenotypes display differential dependence on type I interferon signaling. *J. Leukoc. Biol.* 86: 411–421.
- Escribese, M. M., E. Sierra-Filardi, C. Nieto, R. Samaniego, C. Sánchez-Torres, T. Matsuyama, E. Calderon-Gómez, M. A. Vega, A. Salas, P. Sánchez-Mateos, and A. L. Corbí. 2012. The prolyl hydroxylase PHD3 identifies proinflammatory macrophages and its expression is regulated by activin A. *J. Immunol.* 189: 1946–1954.
- Ruffell, B., N. I. Affara, and L. M. Coussens. 2012. Differential macrophage programming in the tumor microenvironment. *Trends Immunol.* 33: 119–126.
- Takeuchi, O., and S. Akira. 2011. Epigenetic control of macrophage polarization. *Eur. J. Immunol.* 41: 2490–2493.
- Mullican, S. E., C. A. Gaddis, T. Alenghat, M. G. Nair, P. R. Giacomini, L. J. Everett, D. Feng, D. J. Steger, J. Schug, D. Artis, and M. A. Lazar. 2011. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. *Genes Dev.* 25: 2480–2488.
- Stefani, G., and F. J. Slack. 2008. Small non-coding RNAs in animal development. *Nat. Rev. Mol. Cell Biol.* 9: 219–230.
- Croce, C. M. 2009. Causes and consequences of microRNA dysregulation in cancer. *Nat. Rev. Genet.* 10: 704–714.
- Latronico, M. V., and G. Condorelli. 2009. MicroRNAs and cardiac pathology. *Nat. Rev. Cardiol.* 6: 419–429.
- Pandey, A. K., P. Agarwal, K. Kaur, and M. Datta. 2009. MicroRNAs in diabetes: tiny players in big disease. *Cell. Physiol. Biochem.* 23: 221–232.
- Thum, T., C. Gross, J. Fiedler, T. Fischer, S. Kissler, M. Bussen, P. Galuppo, S. Just, W. Rottbauer, S. Frantz, et al. 2008. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. *Nature* 456: 980–984.
- Graff, J. W., A. M. Dickson, G. Clay, A. P. McCaffrey, and M. E. Wilson. 2012. Identifying functional microRNAs in macrophages with polarized phenotypes. *J. Biol. Chem.* 287: 21816–21825.
- Banerjee, S., A. de Freitas, A. Friggeri, J. W. Zmijewski, G. Liu, and E. Abraham. 2011. Intracellular HMGB1 negatively regulates phagocytosis. *J. Immunol.* 187: 4686–4694.
- Bystrom, J., I. Evans, J. Newson, M. Stables, I. Toor, N. van Rooijen, M. Crawford, P. Colville-Nash, S. Farrow, and D. W. Gilroy. 2008. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. *Blood* 112: 4117–4127.
- de Freitas, A., S. Banerjee, N. Xie, H. Cui, K. I. Davis, A. Friggeri, M. Fu, E. Abraham, and G. Liu. 2012. Identification of TLT2 as an engulfment receptor for apoptotic cells. *J. Immunol.* 188: 6381–6388.

24. Yang, S., S. Banerjee, A. de Freitas, Y. Y. Sanders, Q. Ding, S. Matalon, V. J. Thannickal, E. Abraham, and G. Liu. 2012. Participation of miR-200 in pulmonary fibrosis. *Am. J. Pathol.* 180: 484–493.
25. Gibbons, M. A., A. C. MacKinnon, P. Ramachandran, K. Dhaliwal, R. Duffin, A. T. Phythian-Adams, N. van Rooijen, C. Haslett, S. E. Howie, A. J. Simpson, et al. 2011. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. *Am. J. Respir. Crit. Care Med.* 184: 569–581.
26. Jakubzick, C., E. S. Choi, B. H. Joshi, M. P. Keane, S. L. Kunkel, R. K. Puri, and C. M. Hogaboam. 2003. Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. *J. Immunol.* 171: 2684–2693.
27. Prasse, A., D. V. Pechkovsky, G. B. Toews, W. Jungraithmayr, F. Kollert, T. Goldmann, E. Vollmer, J. Müller-Quernheim, and G. Zissel. 2006. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. *Am. J. Respir. Crit. Care Med.* 173: 781–792.
28. Baran, C. P., J. M. Opalek, S. McMaken, C. A. Newland, J. M. O'Brien, Jr., M. G. Hunter, B. D. Bringardner, M. M. Monick, D. R. Brigstock, P. C. Stromberg, et al. 2007. Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. *Am. J. Respir. Crit. Care Med.* 176: 78–89.
29. Guth, A. M., W. J. Janssen, C. M. Bosio, E. C. Crouch, P. M. Henson, and S. W. Dow. 2009. Lung environment determines unique phenotype of alveolar macrophages. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 296: L936–L946.
30. Lacey, D. C., A. Achuthan, A. J. Fleetwood, H. Dinh, J. Roiniotis, G. M. Scholz, M. W. Chang, S. K. Beckman, A. D. Cook, and J. A. Hamilton. 2012. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. *J. Immunol.* 188: 5752–5765.
31. Liao, X., S. M. Haldar, Y. Lu, D. Jeyaraj, K. Paruchuri, M. Nahori, Y. Cui, K. H. Kaestner, and M. K. Jain. 2010. Krüppel-like factor 4 regulates pressure-induced cardiac hypertrophy. *J. Mol. Cell. Cardiol.* 49: 334–338.
32. Chaudhuri, A. A., A. Y. So, N. Sinha, W. S. Gibson, K. D. Taganov, R. M. O'Connell, and D. Baltimore. 2011. MicroRNA-125b potentiates macrophage activation. *J. Immunol.* 187: 5062–5068.
33. Zhuang, G., C. Meng, X. Guo, P. S. Cheruku, L. Shi, H. Xu, H. Li, G. Wang, A. R. Evans, S. Safe, et al. 2012. A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation. *Circulation* 125: 2892–2903.
34. Puig-Kröger, A., E. Sierra-Filardi, A. Domínguez-Soto, R. Samaniego, M. T. Corcuera, F. Gómez-Aguado, M. Ratnam, P. Sánchez-Mateos and A. L. Corbí. 2009. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. *Cancer Res.* 69: 9395–9403.
35. Hou, W., Q. Tian, N. M. Steuerwald, L. W. Schrum, and H. L. Bonkovsky. 2012. The let-7 microRNA enhances heme oxygenase-1 by suppressing Bach1 and attenuates oxidant injury in human hepatocytes. *Biochim. Biophys. Acta* 1819: 1113–1122.
36. Sierra-Filardi, E., M. A. Vega, P. Sánchez-Mateos, A. L. Corbí, and A. Puig-Kröger. 2010. Heme Oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release. *Immunobiology* 215: 788–795.
37. O'Neill, L. A. 2008. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. *Immunol. Rev.* 226: 10–18.
38. Ishii, M., H. Wen, C. A. Corsa, T. Liu, A. L. Coelho, R. M. Allen, W. F. Carson, IV, K. A. Cavassani, X. Li, N. W. Lukacs, et al. 2009. Epigenetic regulation of the alternatively activated macrophage phenotype. *Blood* 114: 3244–3254.
39. Lu, Y. C., I. Kim, E. Lye, F. Shen, N. Suzuki, S. Suzuki, S. Gerondakis, S. Akira, S. L. Gaffen, W. C. Yeh, and P. S. Ohashi. 2009. Differential role for c-Rel and C/EBPbeta/delta in TLR-mediated induction of proinflammatory cytokines. *J. Immunol.* 182: 7212–7221.
40. Litvak, V., S. A. Ramsey, A. G. Rust, D. E. Zak, K. A. Kennedy, A. E. Lampano, M. Nykter, I. Shmulevich, and A. Aderem. 2009. Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. *Nat. Immunol.* 10: 437–443.
41. Maitra, U., L. Gan, S. Chang, and L. Li. 2011. Low-dose endotoxin induces inflammation by selectively removing nuclear receptors and activating CCAAT/enhancer-binding protein δ . *J. Immunol.* 186: 4467–4473.
42. Uderhardt, S., M. Herrmann, O. V. Oskolkova, S. Aschermann, W. Bicker, N. Ipeiz, K. Sarter, B. Frey, T. Rothe, R. Voll, et al. 2012. 12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. *Immunity* 36: 834–846.
43. Park, S. Y., M. Y. Jung, S. J. Lee, K. B. Kang, A. Gratchev, V. Riabov, J. Kzhyshkowska, and I. S. Kim. 2009. Stabilin-1 mediates phosphatidylserine-dependent clearance of cell corpses in alternatively activated macrophages. *J. Cell Sci.* 122: 3365–3373.
44. Geissmann, F., M. G. Manz, S. Jung, M. H. Sieweke, M. Merad, and K. Ley. 2010. Development of monocytes, macrophages, and dendritic cells. *Science* 327: 656–661.
45. Gordon, S., and P. R. Taylor. 2005. Monocyte and macrophage heterogeneity. *Nat. Rev. Immunol.* 5: 953–964.
46. Fadok, V. A., M. L. Warner, D. L. Bratton, and P. M. Henson. 1998. CD36 is required for phagocytosis of apoptotic cells by human macrophages that use either a phosphatidylserine receptor or the vitronectin receptor (alpha v beta 3). *J. Immunol.* 161: 6250–6257.
47. O'Neill, L. A. 2006. How Toll-like receptors signal: what we know and what we don't know. *Curr. Opin. Immunol.* 18: 3–9.
48. Ruffell, D., F. Mourkioti, A. Gambardella, P. Kirstetter, R. G. Lopez, N. Rosenthal, and C. Nerlov. 2009. A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. *Proc. Natl. Acad. Sci. USA* 106: 17475–17480.
49. Chen, X. M., P. L. Splinter, S. P. O'Hara, and N. F. LaRusso. 2007. A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against *Cryptosporidium parvum* infection. *J. Biol. Chem.* 282: 28929–28938.
50. Hu, G., R. Zhou, J. Liu, A. Y. Gong, A. N. Eischeid, J. W. Dittman, and X. M. Chen. 2009. MicroRNA-98 and let-7 confer cholangiocyte expression of cytokine-inducible Src homology 2-containing protein in response to microbial challenge. *J. Immunol.* 183: 1617–1624.
51. Reinhart, B. J., F. J. Slack, M. Basson, A. E. Pasquinelli, J. C. Bettinger, A. E. Rougvie, H. R. Horvitz, and G. Ruvkun. 2000. The 21-nucleotide let-7 RNA regulates developmental timing in *Caenorhabditis elegans*. *Nature* 403: 901–906.
52. Grishok, A., A. E. Pasquinelli, D. Conte, N. Li, S. Parrish, I. Ha, D. L. Baillie, A. Fire, G. Ruvkun, and C. C. Mello. 2001. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control *C. elegans* developmental timing. *Cell* 106: 23–34.
53. Kim, S. J., P. K. Gregersen, and B. Diamond. 2013. Regulation of dendritic cell activation by microRNA let-7c and BLIMP1. *J. Clin. Invest.* pii: 64712.
54. Pottelberge, G. R., P. Mestdagh, K. R. Bracke, O. Thas, Y. M. Durme, G. F. Joos, J. Vandesompele, and G. G. Brusselle. 2011. MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 183: 898–906.
55. Schulte, L. N., A. Eulalio, H. J. Mollenkopf, R. Reinhardt, and J. Vogel. 2011. Analysis of the host microRNA response to *Salmonella* uncovers the control of major cytokines by the let-7 family. *EMBO J.* 30: 1977–1989.
56. Iliopoulos, D., H. A. Hirsch, and K. Struhl. 2009. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. *Cell* 139: 693–706.
57. Polikepahad, S., J. M. Knight, A. O. Naghavi, T. Opl, C. J. Creighton, C. Shaw, A. L. Benham, J. Kim, B. Soibam, R. A. Harris, et al. 2010. Proinflammatory role for let-7 microRNAs in experimental asthma. *J. Biol. Chem.* 285: 30139–30149.
58. Androulidaki, A., D. Iliopoulos, A. Arranz, C. Doxaki, S. Schworer, V. Zacharioudaki, A. N. Margioris, P. N. Tschlis, and C. Tsatsanis. 2009. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. *Immunity* 31: 220–231.
59. Büssing, I., F. J. Slack, and H. Grosshans. 2008. let-7 microRNAs in development, stem cells and cancer. *Trends Mol. Med.* 14: 400–409.
60. Ponomarev, E. D., T. Veremyko, N. Barteneva, A. M. Krichevsky, and H. L. Weiner. 2011. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP- α -PU.1 pathway. *Nat. Med.* 17: 64–70.